It’s been a while since Emblem Cannabis (EMC.V) hit the public markets as one of the big five, making early investors who bought in at $1.15 per share wealthy and setting up the slipstream countless other weedcos have used to burst onto the markets at speed in the months since.
But as big as Emblem’s debut was, it quickly became a mystery.
Why was it sliding? Why did it keep sliding? Why was there no news? Why, when everything else was jumping about, was Emblem so quickly forgotten by the market?
Today? The market remembered.
It’s not based on news. the most recent Emblem news release was March 20, when it announced it was up to over 2000 patients.
PARIS, ONTARIO (Marketwired – March 20, 2017) – Emblem Corp. (TSXV:EMC) (“Emblem” or the “Company”) is pleased to announce that the Company has successfully ramped up its patient acquisition program resulting in a total of 2,091 active and pending patients (net of expired and disabled registrations) having registered since the opening of its patient fulfillment website in late November, 2016. Patient acquisition has been progressively accelerating with 49 patients registered in November, 157 in December, 437 in January, 691 in February and 553 in March to date with a further 246 registrations pending verification.